摘要:
The present invention discloses a modified compound of andrographolide, and particularly discloses a compound shown in formula (I) and (II) or a pharmaceutically acceptable salt thereof.
摘要:
Disclosed herein are compounds of formula (I) that may be specific to PPAR and/or EGF receptors, and methods of making and using same. wherein X is C 1 -C 3 alkylene, optionally substituted with one, two or three substituents selected from halogen or hydroxyl; R 1 is selected from the group consisting of C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 alkenyl, and C 2 -C 6 alkynyl; R 2 is selected from the group consisting of hydrogen and C 1 -C 6 alkyl; R 3 is independently selected, for each occurrence from the group consisting of hydrogen, C 1 -C 6 alkoxy, C 1 -C 6 alkyl, cyano, C 3 -C 6 cycloalkyl, halogen, hydroxyl, and nitro; R 4 is selected from the group consisting of hydrogen and C 1 -C 6 alkyl; R 5 is hydrogen C 1 -C 6 alkyl; or pharmaceutically acceptable salts or N-oxides thereof.
摘要翻译:本文公开了可以对PPAR和/或EGF受体特异的式(I)化合物及其制备和使用方法。 其中X是任选被1,2或3个选自卤素或羟基的取代基取代的C 1 -C 3亚烷基; R 1选自C 1 -C 6烷基,C 3 -C 6环烷基,C 2 -C 6烯基和C 2 -C 6炔基; R 2选自氢和C 1 -C 6烷基; R 3各自独立地选自氢,C 1 -C 6烷氧基,C 1 -C 6烷基,氰基,C 3 -C 6环烷基,卤素,羟基和硝基; R 4选自氢和C 1 -C 6烷基; R 5是氢C 1 -C 6烷基; 或其药学上可接受的盐或N-氧化物。
摘要:
The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
摘要:
An improved process for preparing Carfilzomib of Formula 13 is provided, as well as novel compounds that can be used as intermediates in the process for preparing Carfilzomib.